Summit's PD-1xVEGF interim trial miss surprises analysts, shares tumble

Summit Therapeutics said the squamous cohort in the Harmoni-3 trial missed statistical significance on progression-free survival at a newly added interim analysis, sending the stock down more than 25% in early Friday trading. An independent monitoring committee recommended the study continue, and the company still expects final PFS and interim OS readouts in 2H26. The miss raises uncertainty ahead of the ASCO plenary update for Harmoni-6 and weakens investor confidence in ivonescimab’s global data profile.

Analysis

The market is treating this as a credibility break, not just a statistical hiccup. For SMMT, the key issue is that the asset was priced as a near-term global standard-of-care challenger; once an interim miss appears in the most important cohort, investors will immediately re-rate the probability of a clean late-stage readout and push that binary event further out in time. That matters because biotech multiples are driven less by terminal market size than by how quickly the company can convert a story into a filing, so any slippage in perceived approval probability tends to compress the entire valuation stack, not just the trial in question.

The second-order implication is more interesting for MRK than the tape suggests. A weaker-than-expected global comparator read across the PD-1xVEGF class reduces the odds of a simple “China efficacy translates globally” narrative, which in turn lowers the threat of rapid share loss in first-line metastatic NSCLC. That is not a near-term earnings swing, but it meaningfully improves the durability of Keytruda’s franchise if the class effect proves less portable outside China. ONC’s relevance is indirect: if investor appetite for aggressive oncology combos deteriorates, capital is likely to migrate back toward names with cleaner, more legible catalyst paths and lower translational risk.

The contrarian read is that the interim miss may be more about alpha budgeting and event timing than biology. If the added analysis was deliberately configured with a very small alpha spend, the final read could still clear comfortably if event accumulation and hazard separation improve. In that case the current drawdown is an opportunity to fade panic only after the market finishes repricing the odds of a 2H26 recovery arc.

Near term, the stock can stay weak for days to weeks because the next catalyst is not the final H-3 readout but management’s inability to fully explain the miss. Over the next 1-2 months, the decisive variable is whether outside analysts can reconstruct a plausible statistical design that preserves final success; absent that, every ASCO-related discussion becomes a higher bar event rather than a positive check-in.

Key Decisions for Investors

• Short SMMT on any post-gap bounce over the next 3-10 trading days; use a tight risk cap because the final readout is still distant, but the setup favors continued de-rating until the company re-establishes statistical credibility.
• For event-driven accounts, buy SMMT put spreads 1-3 months out rather than outright puts; the skew is still attractive after a 25%+ reset, and the structure limits decay if the stock stabilizes on analyst defense.
• Maintain or add to MRK versus SMMT as a relative-value long/short pair for the next 1-2 quarters; the trade benefits if investors conclude global efficacy is less replicable than hoped, while downside to MRK is cushioned by its entrenched base business.
• If already long the PD-1xVEGF basket, rotate exposure away from SMMT and toward cleaner oncology catalysts until ASCO; the risk/reward now favors avoiding names where the next data point can only disappoint unless the market is already too bearish.
• Do not chase ONC as a sympathy long immediately; wait for a broader read on whether the selloff is isolated to trial credibility or whether the market is re-rating all China-to-global oncology translational names.